$Bob's and Jbem's Bitchin' Bios

[BioSpecialist]

AQSZF (MC $10 M) 2 Marketed Drugs + 3 close to Approval including a Potential Blockbuster = SUPER LIFETIME OPPORTUNITY !!!!

This undiscovered low float rocket is definitely the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Get some of this Goldmine before she gets discovered .Management alone holding over 16 Million shares Ceo bought 840k shares at 0.30 just a few days ago .GLTA


Aequus Pharma (AQS.V) (AQSZF)

Market-Cap: $10 M
Price: 0.21

Shares out: 54 Million


Presentation August 2016
http://www.aequuspharma.ca/Investors/Aequus%20Pharmaceuticals%20August%202016.pdf


Monster Pipeline
http://www.aequuspharma.ca/_images/content/Slide1.PNG?Action=thumbnail&algorithm=fill_proportional&width=750


Tacrolimus IR

Aequus initiated promotional efforts for tacrolimus IR in December, 2015 •Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)


Vistitan
•Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) •The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.


Topiramate XR (Epilepsy and Migraine) NDS submission to Health Canada in 1Q 2017


Oxcarbazepine XR (Epilepsy) NDS submission to Health Canada in 1Q 2017


NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License(If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)


AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse.